News

The XXIX Convention of the Spanish Atherosclerosis Society (SEA) took place in Granada last May, and its scientific committee chose another of the I+D projects developed in Biosfer Teslab to be presented as an oral communication. The Communication title is “Standard values of number and size of lipoprotein particles per age and gender, using Nuclear… Read More »Standard values of number and size of lipoprotein particles per age and gender, using Nuclear Magnetic Resonance

In May, the XXIX Convention of the Spanish Atherosclerosis Society (SEA) took place in Granada, and its scientific committee chose one of the I+D projects developed in Biosfer Teslab to be presented as an oral communication. The presented Communication, whose title is “MEtabolomics characterization for patients with Rheumatoid Arthritis (RA) using 1H-Nuclear magnetic resonance (1H… Read More »Metabolomics characterization for patients with Rheumatoid Arthritis using spectroscopy

Biosfer Teslab took part in the XXIX National Convention of the Spanish Atherosclerosis Society (SEA), held this past May. Specifically, the Liposcale test was the main topic of the Round Table with the presence of Fernández Pardo, Luis Masana Marín, Domingo Orozco and Núria Amigó Grau. More information here.

On the 21th of May, Biosfer Teslab took part in the 8th Cardiovascular Meeting of SEMERGEN, in Santander. Nuria Amigó took part in a session which name was “The significance of the size of lipoproteins in cardiovascular risk filtering. More information here.

The Research Program of CIBERDEM is focused on the study of the epidemiology of diabetes mellitus; genetics, epigenetics and related environmental factors with this pathology, and the associated molecular mechanisms to the onset and progress of the cronical complications of the diabetes. In addition, in the framework of this program, there are other nutritional issues… Read More »The Di@bet.es 2 study will define risk scales that will let us apply prevention programs for less people, but better targeted

Biosfer Teslab was awarded with one of the Premis Gresol for Young talents in front of 250 people at Flash Back room, Salou, from the Gresol Fundation. These prizes reclaim the talent of entrepreneurs and professionals from the regions of Camp de Tarragona and reinforce the values of the business world. More information here.

Biosfer to Boston, one of the 20 finalists projects of the international startups acceleration program, The Big Booster More information here.

News about Biosfer Teslab appeared in the reportage of the la Vanguardia newspaper, 25 of October, 2015, it’s title was “Un test més efectiu per al ‘colesterol dolent’” that means “A more efective test for the ‘bad cholesterol’” More information here.

Biosfer Teslab, an in vitro diagnostic company that develops novel NMR-based tests to improve cardiovascular risk assessment in patients at high cardio-metabolic risk, is looking for candidates to join our operations team. The company arises from the research carried out at the Metabolomics Platform and the Lipids and Atherosclerosis Research Unit from the Rovira i… Read More »Open call to join our operations team

Biosfer Teslab, an in vitro diagnostic company that develops novel NMR-based tests to improve cardiovascular risk assessment in patients at high cardio-metabolic risk, is looking for Industrial Doctorate candidates. The company arises from the research carried out at the Metabolomics Platform and the Lipids and Atherosclerosis Research Unit from the Rovira i Virgili University and… Read More »Open call for an Industrial Doctorate